$5.46▾ 6.98%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$3.65cash per $1 profit
Strong
It turns every reported profit-dollar into real cash, and then some.
Valuation
36th pctvs its own history
Fair
Its valuation is around the middle of its own recent range.
Revenue growth
+6.0%year over year
Healthy
Revenue is growing at a steady pace.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Regencell Bioscience Holdings Limited turns 365¢ of every reported profit-dollar into real cash. Revenue is growing at a steady pace. Its valuation is around the middle of its own recent range.
Key numbers
Valuation
EPS (TTM)$0.72
TTM (trailing 12 months, through fiscal Q4 FY2017)
Profitability
Net margin3.6%
TTM (trailing 12 months, through fiscal Q4 FY2017)
Size
Revenue (TTM)$3.16B
TTM (trailing 12 months, through fiscal Q4 FY2017)
Recent news
DEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
FSK DEADLINE NOTICE: ROSEN, A RANKED AND LEADING FIRM, Encourages FS KKR Capital Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – FSK
RGC UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026
Signals and key numbers are from the fiscal Q4 FY2017 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.